C
26.23
0.95 (3.76%)
| 前收盘价格 | 25.28 |
| 收盘价格 | 25.70 |
| 成交量 | 617,951 |
| 平均成交量 (3个月) | 1,399,791 |
| 市值 | 1,999,389,440 |
| 价格/销量 (P/S) | 1.48 |
| 股市价格/股市净资产 (P/B) | 2.80 |
| 52周波幅 | |
| 利润日期 | 13 May 2025 |
| 营业利益率 (TTM) | -8,344.08% |
| 稀释每股收益 (EPS TTM) | -1.41 |
| 季度收入增长率 (YOY) | 45,500.00% |
| 总债务/股东权益 (D/E MRQ) | 0.03% |
| 流动比率 (MRQ) | 35.30 |
| 营业现金流 (OCF TTM) | -78.71 M |
| 杠杆自由现金流 (LFCF TTM) | -59.08 M |
| 资产报酬率 (ROA TTM) | -15.02% |
| 股东权益报酬率 (ROE TTM) | -19.18% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | CG Oncology, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.0
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.00 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.16% |
| 机构持股比例 | 98.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2025 | 6,371,669 |
| Foresite Capital Management Vi Llc | 31 Mar 2025 | 2,221,474 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 75.00 (HC Wainwright & Co., 185.93%) | 购买 |
| 75.00 (Cantor Fitzgerald, 185.93%) | 购买 | |
| 中 | 60.00 (128.75%) | |
| 低 | 23.00 (Scotiabank, -12.31%) | 保留 |
| 平均值 | 55.67 (112.24%) | |
| 总计 | 5 购买, 1 保留 | |
| 平均价格@调整类型 | 26.17 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 19 May 2025 | 52.00 (98.25%) | 购买 | 24.86 |
| 07 Mar 2025 | 55.00 (109.68%) | 购买 | 26.72 | |
| JP Morgan | 02 May 2025 | 41.00 (56.31%) | 购买 | 29.05 |
| RBC Capital | 29 Apr 2025 | 68.00 (159.25%) | 购买 | 26.94 |
| Cantor Fitzgerald | 28 Apr 2025 | 75.00 (185.93%) | 购买 | 27.97 |
| HC Wainwright & Co. | 28 Apr 2025 | 75.00 (185.93%) | 购买 | 27.97 |
| 31 Mar 2025 | 75.00 (185.93%) | 购买 | 24.49 | |
| Scotiabank | 16 Apr 2025 | 23.00 (-12.31%) | 保留 | 20.22 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合